CONCOMITANT THERAPY WITH IXEKIZUMAB PLUS TIRZEPATIDE IN ADULTS WITH PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY DEMONSTRATED SUPERIOR DISEASE CONTROL COMPARED TO IXEKIZUMAB ALONE: RESULTS FROM THE PH3B TOGETHER-PSA TRIAL

E. Filippi[1], J. F. Merola[2], P. Mease[3], A. Kivitz[4], N. Sattar[5], L. C. Coates[6], C. E. Kartman[7], P. Fischer[7], L. Sun[7], A. Cardoso[7], M. C. Genovese[7], A. Ogdie[8]

[1]Eli Lilly Italia S.p.A, Florence, Italy; [2]Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O'Donnell School of Public Health, Dallas, TX, USA; [3]Providence Swedish Medical Center, Seattle, WA, USA; [4]Altoona Center for Clinical Research, Duncansville, PA, USA; [5]School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; [6]Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; [7]Eli Lilly and Company, Indianapolis, IN, USA; [8]Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Keywords: *Together-Psa Trial, Psoriatic Arthritis.*

Background. Overweight and obesity occurs in 72-82%[1,2] of patients with psoriatic arthritis (PsA) and is associated with worse clinical outcomes and increased comorbidities[3]. We evaluated efficacy and safety of ixekizumab and tirzepatide (IXE+TZP) compared to ixekizumab (IXE) in adults with active PsA and overweight (BMI>27-<30 kg/m2) with ≥1 weight-related comorbidity or obesity (BMI≥30 kg/m2). Type of Study: TOGETHER-PsA (NCT06588296) is a Phase 3b, randomized, 52-week trial.

Methods. Participants were randomized 1:1 to IXE+TZP or IXE (open-label) using FDA-approved doses. Primary outcome was week 36 simultaneous achievement of ACR50 and ≥10% weight reduction. Key secondaries included ACR50.

Results. Of participants on IXE+TZP (n=138) and IXE (n=133), mean age was 55.0 years, 69.7% were female, BMI was 37.6 kg/m2, 71.6% had psoriasis, and 18.8% had failed ≥2 classes of advanced therapies. 31.7% participants achieved primary outcome with IXE+TZP *versus* 0.8% for IXE (p<0.001). A meaningful difference in ACR50 was observed in IXE+TZP (33.5%) *versus* IXE alone (20.4%) (multiplicity-controlled p=0.020) with a significant improvement (p<0.05) seen as early as week 4. Improvements were demonstrated in PASI 75/90/100 for IXE+TZP and IXE alone, with IXE+TZP demonstrating a significant difference in absolute PASI change from baseline (p<0.01). Significant improvements were observed in physical function (HAQ-DI; p<0.001), FACIT-fatigue (p<0.01), SF-36 MCS (p<0.05) and PCS (p<0.001). Adverse events (AEs) aligned with established drug profiles. Treatment discontinuations due to AEs were comparable among treatment groups.

Conclusions. Significant comprehensive improvement in disease activity was demonstrated with IXE+TZP compared to IXE alone in active PsA, with no new safety concerns.

References

1. Eder L, Thavaneswaran A, Chandran V, et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(5):813-7.
2. Curtis J, Rodriguez P, Probst J, et al. Quantifying the Obesity-Psoriatic Arthritis Nexus: Prevalence, Incidence, and Comorbidities from 19.9 Million US Patients (2018-2024): presentation at RWCS 2026 on 11-14 February 2026 in Maui, Hawaii, USA.
3. Kumthekar A, Ogdie A. Obesity and Psoriatic Arthritis: A Narrative Review. Rheumatol Ther. 2020;7(3):447-56.